Cargando…
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group,...
Autores principales: | Hjorth-Hansen, Henrik, Stenke, Leif, Söderlund, Stina, Dreimane, Arta, Ehrencrona, Hans, Gedde-Dahl, Tobias, Gjertsen, Bjørn Tore, Höglund, Martin, Koskenvesa, Perttu, Lotfi, Kourosh, Majeed, Waleed, Markevärn, Berit, Ohm, Lotta, Olsson-Strömberg, Ulla, Remes, Kari, Suominen, Merja, Simonsson, Bengt, Porkka, Kimmo, Mustjoki, Satu, Richter, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365700/ https://www.ncbi.nlm.nih.gov/pubmed/25082346 http://dx.doi.org/10.1111/ejh.12423 |
Ejemplares similares
-
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022) -
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
por: Ilander, M, et al.
Publicado: (2017) -
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019) -
Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
por: Kekäle, Meri, et al.
Publicado: (2014) -
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)